Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Breaking News

Tesla, GE and F5 Networks Rise Premarket; UPS Falls

VIVUS (VVUS) Loss Narrower Than Expected, Revenues Up Y/Y

By Zacks Investment ResearchStock MarketsMay 03, 2017 10:37PM ET,-revenues-up-y-y-200187129
VIVUS (VVUS) Loss Narrower Than Expected, Revenues Up Y/Y
By Zacks Investment Research   |  May 03, 2017 10:37PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

VIVUS Inc. (NASDAQ:VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents.

Shares of the biotech company rose almost 3% in aftermarket hours on Wednesday. However, so far this year, Vivus’ shares have underperformed the Zacks classified Medical - Biomedical and Genetics. The stock fell 10.4% during the period, while the industry witnessed a gain of 5.3%.

Quarterly revenues increased 76.3% to $27 million form the year-ago period. It included a one-time payment of $5 million for a license to certain clinical data related to phentermine, the active pharmaceutical ingredients (API) for Qsymia.

Quarter in Detail

The company’s weight management drug Qsymia generated net product sales of $17.6 million, up almost 42% from the year-ago period. The company recognized net product revenues of $7.3 million related to units of Qsymia shipped prior to Jan 1, 2017 due to a change in revenue recognition methodology by the company. Also, the company expects the new method to increase volatility of Qsymia sales.

Supply and royalty revenues from Stendra/Spedra were $4.4 million, up 50.8% from the year-ago period due to an increase in supply revenues as a number of orders placed by commercialization partners in this quarter were better than the year-ago period.

General and administrative expense was $6.2 million, down 20% year over year mainly attributable to cost control initiatives undertaken by the company. Research and development expense increased 120% to $2.2 million in the reported quarter due to payment of license fees to Selten Pharma for the development of tacrolimus and ascomycin for the treatment of pulmonary arterial hypertension (PAH).

In Jan 2017, Vivus acquired exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin from Selten Pharma, Inc. for the treatment of PAH and related vascular diseases.

In Jan 2017, Vivus granted a license to Hetero to manufacture and commercialize an authorized generic version of Stendra no earlier than Oct 29, 2024. Hetero had previously filed an abbreviated new drug application (ANDA) to get approval to market a generic version of Stendra. Also, in March this year, the company announced an agreement with Sanofi (NYSE:SNY) to reacquire the commercial rights to Stendra in Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.

VIVUS, Inc. Price, Consensus and EPS Surprise

VIVUS, Inc. Price, Consensus and EPS Surprise | VIVUS, Inc. Quote

Zacks Rank & Key Picks

Vivus currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Grifols, S.A. (NASDAQ:GRFS) and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) . While Infinity sports a Zacks Rank #1 (Strong Buy), Grifols carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Grifols’ earnings estimates increased 1.8% to $1.16 for 2017 and 2.4% to $1.28 for 2018 over the last 60 days. Its share price is up approximately 32.9% year to date.

Infinity’s loss estimates narrowed 27.9% to $1.03 for 2017 and 13.1% to $1.52 for 2018 over the last 60 days. Its share price is up 40.7% year to date.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Sanofi (SNY): Free Stock Analysis Report

VIVUS, Inc. (VVUS): Free Stock Analysis Report

Grifols, S.A. (GRFS): Free Stock Analysis Report

Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report

Original post

Zacks Investment Research
VIVUS (VVUS) Loss Narrower Than Expected, Revenues Up Y/Y

Related Articles

VIVUS (VVUS) Loss Narrower Than Expected, Revenues Up Y/Y

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email